Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 497Neoplasms 302Breast Neoplasms 294Colorectal Neoplasms 228Neoplasm Metastasis 194Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 159Multiple Myeloma 158Recurrence 131Melanoma 125Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 104Stomach Neoplasms 102Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 84Lymphoma, Non-Hodgkin 84Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Lymphoma 62Parkinson Disease 4, Autosomal Dominant Lewy Body 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

pembrolizumab 1Radiotherapy, Intensity-Modulated 1LY3300054 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Camurati-Engelmann Syndrome × 90 days × Clear all
NCT06788990 2026-06-02

FORTIFI-HN01

Bicara Therapeutics

Phase 2/3 Recruiting
650 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT06487624 2026-04-13

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

FBD Biologics Limited

Phase 1 Recruiting
50 enrolled
Lymphoid

Camurati-Engelmann Syndrome, Hodgkin Disease, Neoplasms

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡